/Bio-Techne%20Corp%20sign-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. With a market cap of $10.9 billion, Bio-Techne operates through Protein Sciences, and Diagnostics & Spatial Biology segments.
The biotech major has underperformed the broader market over the past year. Bio-Techne stock prices declined 10.9% in 2024 and gained 8.1% over the past year, lagging behind the S&P 500 Index’s ($SPX) surge of 24.1% on a YTD basis and 30.1% over the past 52 weeks.